What is the therapeutic action of a combination inhaler containing a long-acting beta2-agonist and a steroid?

What is the therapeutic action of a combination inhaler containing a long-acting beta2-agonist and a steroid?

• A. The medications provide bronchodilation and reduced airway inflammation.
• B. The medications act in combination to decrease airway inflammation.
• C. They provide bronchodilation only with no anti-inflammatory effect.
• D. The two medications potentiate each other and provide longer-acting symptom control.

Answer: (A)

These combination inhalers work by addressing both bronchoconstriction and airway inflammation. The long-acting beta2-agonist relaxes the smooth muscle of the airways, producing bronchodilation and easier breathing. The corticosteroid reduces airway inflammation by decreasing inflammatory cell activity and mediators, which lowers edema and mucus production over time. Together, they provide both immediate airway opening and ongoing anti-inflammatory control, making bronchodilation with reduced airway inflammation the best description of their therapeutic action. While the steroid component targets inflammation and the bronchodilator provides dilation, the most complete answer is that the combination delivers both effects.

These combination inhalers work by addressing both bronchoconstriction and airway inflammation. The long-acting beta2-agonist relaxes the smooth muscle of the airways, producing bronchodilation and easier breathing. The corticosteroid reduces airway inflammation by decreasing inflammatory cell activity and mediators, which lowers edema and mucus production over time. Together, they provide both immediate airway opening and ongoing anti-inflammatory control, making bronchodilation with reduced airway inflammation the best description of their therapeutic action. While the steroid component targets inflammation and the bronchodilator provides dilation, the most complete answer is that the combination delivers both effects.